Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tomas Merta"'
Autor:
Hana Palova, Anirban Das, Petra Pokorna, Viera Bajciova, Zdenek Pavelka, Marta Jezova, Karol Pal, Jose R. Dimayacyac, Logine Negm, Lucie Stengs, Vanessa Bianchi, Klara Vejmelkova, Kristyna Noskova, Marie Jarosova, Sona Mejstrikova, Peter Mudry, Michal Kyr, Tomas Merta, Pavel Tinka, Klara Drabova, Stefania Aulicka, Robin Jugas, Uri Tabori, Ondrej Slaby, Jaroslav Sterba
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Constitutional mismatch repair deficiency (CMMRD) is a rare syndrome characterized by an increased incidence of cancer. It is caused by biallelic germline mutations in one of the four mismatch repair genes (MMR) genes: MLH1, MSH2, MSH6, or P
Externí odkaz:
https://doaj.org/article/b0a2950947714c9188792348f38d31f7
Autor:
Kristyna Polaskova, Tomas Merta, Alexandra Martincekova, Danica Zapletalova, Michal Kyr, Pavel Mazanek, Zdenka Krenova, Peter Mudry, Marta Jezova, Jiri Tuma, Jarmila Skotakova, Ivana Cervinkova, Dalibor Valik, Lenka Zdrazilova-Dubska, Hana Noskova, Karol Pal, Ondrej Slaby, Pavel Fabian, Sarka Kozakova, Jakub Neradil, Renata Veselska, Veronika Kanderova, Ondrej Hrusak, Tomas Freiberger, Giannoula Lakka Klement, Jaroslav Sterba
Publikováno v:
Frontiers in Oncology, Vol 9 (2020)
In order to identify reasons for treatment failures when using targeted therapies, we have analyzed the comprehensive molecular profiles of three relapsed, poor-prognosis Burkitt lymphoma cases. All three cases had resembling clinical presentation an
Externí odkaz:
https://doaj.org/article/5c281799cb3e41e29ab698bc35a5380e
Autor:
Michal Kyr, Kristyna Polaskova, Zuzana Kuttnerova, Tomas Merta, Jakub Neradil, Jitka Berkovcova, Ondrej Horky, Marta Jezova, Renata Veselska, Giannoula Lakka Klement, Dalibor Valik, Jaroslav Sterba
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Introduction: The individualization of treatment is attractive, especially in children with high-risk cancer. In such a rare and very heterogeneous group of diseases, large population-based clinical randomized trials are not feasible without internat
Externí odkaz:
https://doaj.org/article/86696cb98eda4de6be30002db1ea2e5d
Autor:
Petra Pokorna, Giannoula Lakka Klement, Alzbeta Vasikova, Veronika Kanderova, Marta Jezova, Kristyna Noskova, Peter Mudry, Michal Kyr, Tomas Merta, Viera Bajciova, Zdenka Krenova, Hana Palova, Dalibor Valik, Lenka Zdrazilova Dubska, Ondrej Slaby, Jaroslav Sterba
Publikováno v:
JCO Precision Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98da9c29e79ecd4b8b6f9984514428d3
https://doi.org/10.1200/po.21.00525
https://doi.org/10.1200/po.21.00525
Autor:
Petra Pokorna, Hana Palova, Tina Catela Ivkovic, Sona Adamcova, Michal Kyr, Vojtech Bystry, Robin Jugas, Karolina Trachtova, Dagmar Al Tukmachi, Tomas Merta, Jaroslav Juracek, Jiri Sana, Sona Mejstrikova, Marta Jezova, Peter Mudry, Zdenek Pavelka, Jaroslav Sterba, Ondrej Slaby
Publikováno v:
Cancer Research. 82:76-76
Despite the great achievements in treating pediatric cancer patients in the last several decades, approximately one fifth of patients remains uncurable using standard therapeutic modalities and require search for innovative therapeutic approaches. Ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8564a0b00867d6b5fb2c6294abff7eea
https://doi.org/10.1158/1538-7445.am2022-76
https://doi.org/10.1158/1538-7445.am2022-76
Autor:
Pavel Zerhau, Marta Jezova, Arpad Kerekes, Petr Jabandziev, Katerina Slaba, Jan Papez, Denisa Pavlovská, Jiri Starha, Hana Pálová, Tomas Merta, Ondrej Slaby, Jaroslav Sterba, Tomas Jurencak, Terezia Haluskova, Martin Sterba
Publikováno v:
Genes
Genes, Vol 12, Iss 220, p 220 (2021)
Genes, Vol 12, Iss 220, p 220 (2021)
Spindle cell hemangioma is a benign vascular tumor typically occurring in the dermis or subcutis of distal extremities as red–brown lesions that can grow in both size and number over time. They can be very painful and potentially disabling. A famil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5db5c341bb185d452c0819d7eab7a28
http://europepmc.org/articles/PMC7913579
http://europepmc.org/articles/PMC7913579
Autor:
Tekla Hornakova, Kristyna Polaskova, Tina Catela Ivkovic, Leos Kren, Sona Adamcova, Ondrej Slaby, Hana Nosková, Karol Pál, Jaroslav Sterba, Peter Múdry, Tomas Merta, Marta Jezova, Michal Kyr
Publikováno v:
Cancers
Cancers, Vol 12, Iss 1, p 230 (2020)
Volume 12
Issue 1
Cancers, Vol 12, Iss 1, p 230 (2020)
Volume 12
Issue 1
Background: Tumor mutational burden (TMB) is an emerging genomic biomarker in cancer that has been associated with improved response to immune checkpoint inhibitors (ICIs) in adult cancers. It was described that variability in TMB assessment is intro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10948863c8c9a851a00e5a8b5f5fe02b
https://doi.org/10.3390/cancers12010230
https://doi.org/10.3390/cancers12010230
Autor:
T. Horňáková, Karol Pál, Dana Knoflíčková, Tomas Merta, Ondřej Slabý, Jaroslav Štěrba, Soňa Adamcová, Andrea Grioni, Klára Vejmělková, Zdenek Pavelka, Peter Múdry, Hana Nosková
Publikováno v:
Annals of Oncology. 30:vii28-vii29
Background The necessary condition for the application of precision oncology approach into the routine is a detailed molecular characterization of the tumour. In our study, we explored clinical applicability of both whole exome sequencing (WES) and F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd42cfab7452bc77f31b7a66871805f0
https://doi.org/10.1093/annonc/mdz413.102
https://doi.org/10.1093/annonc/mdz413.102